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HER2 and basal subtypes in BRCA-associated
carcinomas
Siddhartha Deb1,2,3*, Nicholas Jene1, kConFab investigators4 and Stephen B Fox1,3,4Abstract
Background: Male breast cancer (MBC) is an uncommon and relatively uncharacterised disease accounting for <1%
of all breast cancers. A significant proportion occurs in families with a history of breast cancer and in particular
those carrying BRCA2 mutations. Here we describe clinicopathological features and genomic BRCA1 and BRCA2
mutation status in a large cohort of familial MBCs.
Methods: Cases (n=60) included 3 BRCA1 and 25 BRCA2 mutation carries, and 32 non-BRCA1/2 (BRCAX) carriers with
strong family histories of breast cancer. The cohort was examined with respect to mutation status,
clinicopathological parameters including TNM staging, grade, histological subtype and intrinsic phenotype.
Results: Compared to the general population, MBC incidence was higher in all subgroups. In contrast to female
breast cancer (FBC) there was greater representation of BRCA2 tumours (41.7% vs 8.3%, p=0.0008) and
underrepresentation of BRCA1 tumours (5.0% vs 14.4%, p=0.0001). There was no correlation between mutation
status and age of onset, disease specific survival (DSS) or other clincopathological factors. Comparison with sporadic
MBC studies showed similar clinicopathological features. Prognostic variables affecting DSS included primary
tumour size (p=0.003, HR:4.26 95%CI 1.63-11.11), age (p=0.002, HR:4.09 95%CI 1.65-10.12), lymphovascular (p=0.019,
HR:3.25 95%CI 1.21-8.74) and perineural invasion (p=0.027, HR:2.82 95%CI 1.13-7.06). Unlike familial FBC, the
histological subtypes seen in familial MBC were more similar to those seen in sporadic MBC with 46 (76.7%) pure
invasive ductal carcinoma of no special type (IDC-NST), 2 (3.3%) invasive lobular carcinomas and 4 (6.7%) invasive
papillary carcinoma. A further 8 (13.3%) IDC-NST had foci of micropapillary differentiation, with a strong trend for
co-occurrence in BRCA2 carriers (p=0.058). Most tumours were of the luminal phenotype (89.7%), with infrequent
HER2 (8.6%) and basal (1.7%) phenotype tumours seen.
Conclusion: MBC in BRCA1/2 carriers and BRCAX families is different to females. Unlike FBC, a clear BRCA1
phenotype is not seen but a possible BRCA2 phenotype of micropapillary histological subtype is suggested.
Comparison with sporadic MBCs shows this to be a high-risk population making further recruitment and
investigation of this cohort of value in further understanding these uncommon tumours.
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Table 1 Mutation carrier status and male breast cancer
with the kConFab cohort
BRCA1 BRCA2 Non-BRCA1/2
All males in kConFab registry 429 339 19137
Breast Cancers 5 (1.2%) 35 (10.3%) 78 (0.4%)
Pathology Available 3 25 32
Table 2 Characterisation of BRCA1 and 2 mutations of
males included within this study
Gene Mutation Effect
BRCA1 BRCA1 del exons 21_24 LGR
BRCA1 2798_2801 del GAAA (STOP 998) P
BRCA1 5382_5383 ins C (STOP 1829) P
BRCA2 BRCA2 del exons 1_2 LGR
BRCA2 del exons 14_16 LGR
BRCA2 2988 del C (STOP 959) P
BRCA2 2988 del C (STOP 959) P
BRCA2 5873 C>A (S1882X) P
BRCA2 5950_5951 del CT (STOP 1909) P
BRCA2 5950_5951 del CT (STOP 1909) P
BRCA2 6024_6025 del TA (STOP 1943) P
BRCA2 6503_6504 del TT (STOP 2098) P
BRCA2 6714_6717 del ACAA (STOP 2166) P
BRCA2 6854_6855 del TA (STOP 2223) P
BRCA2 6971_6983 del ATGCCACACATTC (STOP 2275) P
BRCA2 698_702 del AGTCA (STOP 180) P
BRCA2 7708 C>T (R2494X) P
BRCA2 8168_8169 ins C (STOP 2661) P
BRCA2 9132 del C (STOP 2975). P
BRCA2 9161 C>A (S2978X) P
BRCA2 9610 C>T (R3128X) P
BRCA2 9610 C>T (R3128X) P
BRCA2 983_986 del ACAG (STOP 275) P
BRCA2 995 del C (STOP 276) P
BRCA2 del exons 1_27 P
BRCA2 IVS 7–1 G>A P
P BRCA2 8525 del C (STOP 2776). P
BRCA2 8714 A>G (del exon 19) UV
Classification of Variants: P = Pathogenic, LGR = Large Genomic
Rearrangement, UV = Unclassified Variant.
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Male breast cancer (MBC) is an infrequent and poorly
characterised disease. Limited data to date suggests it is
epidemiologically and biologically different from female
breast cancer (FBC) but it is unknown whether current
paradigms and treatment of female disease can be extra-
polated to the pathobiology and management of MBC
and vice versa. Although some recent large MBC studies
have been undertaken, these are population-based and
this current report is the largest to describe the geno-
type, tumour phenotype, complete clinicopathological
parameters and survival in MBC from high-risk families.
Accounting for less than 1% of all male cancers, and
0.65% of all breast tumours [1-3], the incidence of MBC
has increased steadily from approximately 0.86 to 1.06
per 100,000 males over a 26 year period [4,5] There is
controversy surrounding mortality with some suggestion
that MBC disproportionately accounts for a higher num-
ber of deaths than breast cancer in women [4-7] while
other studies suggest parity when comparing age and
stage matched cases [8].
Inherited risk factors for MBC appears to be a more
significant contributor than in women with estimates of
10% of all MBC cases arising with a family pedigree sug-
gestive of a genetic predisposition [2,9-11]. Unlike
women, BRCA2 germline mutation in men confers a sig-
nificantly higher lifetime risk of developing breast cancer
than BRCA1 [2,9-11]. Other genes also implicated in the
development of MBC including PTEN [12], P53 [13] and
CHEK2 1100delC [14]. Kleinfelter’s syndrome (XXY)
[15], environmental and hormonal states that alter the
ratio of androgens to estrogens are also thought to con-
tribute to MBC [16]. Recent meta-analysis has also
shown an association between previous breast disease, in
particular gynaecomastia, and occurrence of MBC [17].
It is still unclear, however, whether this is a; precursor
lesion, a risk factor for MBC or whether the aetiology
and pathogenesis is the same for both conditions.
Despite extensive knowledge about female BRCA1,
BRCA2 and other inherited familial breast tumours at
present, little is know of male tumours from high-risk fam-
ilies. Comparison of sporadic tumours in both sexes shows;
a steady linear increase in incidence in men with age in
contrast to the bimodal distribution seen in FBC [2,3,18],
an older median age of diagnosis in men [6,8,18], more
advanced stage-related tumour characteristics (tumour size
>2cm, positive axillary nodes) [2,18] but with more
favourable histopathological characteristics (lower tumour
grade) and biology (hormone receptor positive tumours)
[2,18]. Most MBC studies have been performed with
cohorts predominantly composed of “sporadic” population
based patients whereas this study is focused on one of the
largest groups of MBCs arising in high-risk families evaluat-
ing both clinicopathological and genetic associations.Methods
Study group
Males with breast cancer were obtained from the
kConFab repository (http://www.kconfab.org). Criteria
for admission to the kConFab study has been previously
published [19] (Additional file 1: Table S1) and patients
were attained from within Australia and New Zealand
between 1998 and 2009. The cases used in the analysis
Table 3 Clinicopathological features
All patients (n=60) BRCA1 (n=3) BRCA2 (n=25) BRCAX (n=32) P-value
AGE AT DIAGNOSIS
Median 62.5 (30.1 - 85.6) 65.6 (49.5-80.1) 61 (31.0 - 85.7) 63.2 (30.1 - 81.8)
<60 yoa 26 (43.3%) 1 (33.3%) 11 (44.0%) 14 (43.8%)
>60 yoa 34 (56.7%) 2 (66.6%) 14 (56.0%) 18 (56.3%) NS
DISEASE SPECIFIC MORTALITY 35.0% 33.3% 40.0% 31.3%
SIDE
Right 36 (60.0%) 1 (33.3%) 17 (68.0%) 18 (56.2%)
Left 24 (40.0%) 2 (66.7%) 8 (32.0%) 14 (43.8%) NS
Unifocal 56 (93.3%) 3 (100%) 22 (88.0%) 31 (96.9%)
Multifocal 2 (3.3%) 0 2 (8.0%) 0
Bilateral 2 (3.3%) 0 1 (4.0%) 1 (3.1%) NS
HISTOLOGICAL SUBTYPE
Invasive Ductal Carcinoma - No special type 46 (76.7%) 2 (66.7%) 18 (72%) 28 (87.5%)
IDC with Micropapillary component 8 (13.3%) 0 6 (24%) 2 (6.3%)
Invasive Papillary Carcinoma 4 (6.7%) 1 (33.3%) 1 (4%) 2 (6.3%)
Invasive Lobular Carcinoma 2 (3.3%) 0 0 2 (6.3%) NS
BRE GRADE
1 2 (3.3%) 0 1 (4%) 1 (3.1%)
2 31 (51.7%) 0 12 (48%) 19 (59.4%)
3 27 (45.0%) 3 (100%) 12 (48%) 12 (37.5%) NS
ER STATUS (ALLRED 0-8)
0 1 (1.7%) 0 0 1 (3.3%)
1-5. 5 (8.6%) 1 (33.3%) 2 (8.0%) 2 (6.7%)
6-8. 52 (89.7%) 2 (66.7%) 23 (92.0%) 27 (90.0%)
NA 2 0 0 2 NS
PR STATUS (ALLRED 0-8)
0 5 (8.8%) 0 1 (4%) 4 (13.8%)
1-5. 8 (14.0%) 0 5 (20%) 3 (10.3%)
6-8. 44 (77.2%) 3 (100%) 19 (76%) 22 (75.9%)
NA 3 0 0 3 NS
HER2
Amplification 5 (9.1%) 0 2 (8.3%) 3 (10.7%)
Non-amplified 50 (90.9%) 3 (100%) 22 (91.7%) 25 (89.3%)
NA 5 0 1 4 NS
PHENOTYPE
Basal 1 (1.7%) 0 0 1 (3.3%)
Luminal 52 (89.7%) 3 (100%) 23 (92.0%) 26 (86.7%)
HER2 5 (8.6%) 0 2 (8.0%) 3 (10.0%)
NA 2 0 0 2 NS
TUMOUR SIZE
Median 17mm (2-50mm) 15mm (9-25mm) 17mm (6-40mm) 16 (2-50mm)
TUMOUR STAGE
T1a 1 (1.7%) 0 0 1 (3.1%)
T1b 8 (13.3%) 1 (33.3%) 4 (16.0%) 3 (9.4%)
T1c 31 (51.7%) 1 (33.3%) 10 (40.0%) 19 (59.4%)
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Table 3 Clinicopathological features (Continued)
T2 19 (31.7%) 1 (33.3%) 11 (44.0%) 7 (21.9%)
T3 1 (1.7%) 0 0 1 NS
LYMPHOVASCULAR INVASION
Absent 32 (57.1%) 2 (66.7%) 14 (60.9%) 16 (53.3%)
Present 24 (42.9%) 1 (33.3%) 9 (39.1%) 14 (46.7%)
NA 4 0 2 2 NS
PERINEURAL INVASION
Absent 31 (56.4%) 3 (100%) 12 (50.0%) 16 (57.1%)
Present 24 (43.6%) 0 12 (50.0%) 12 (42.9%)
NA 5 0 1 4 NS
PAGET'S DISEASE OF NIPPLE
Absent 44 (84.6%) 2 (100%) 19 (86.4%) 23 (82.1%)
Present 8 (15.4%) 0 3 (13.6%) 5 (17.9%)
NA 8 1 3 4 NS
NODAL STATUS
Cases with nodes examined 46 (76.7%) 3 (100%) 20 (80.0%) 23 (71.9%)
Cases with positive nodes 20 (43.4%) 2 (66.7%) 9 (45.0%) 9 (39.1%) NS
Average numbers of nodes examined per case 12.9 (1-30) 16.3 (13-24) 15.9 (1-30) 10.1 (1-29)
NODAL STAGE
N0 26 (56.5%) 1 (33.3%) 11 (55.0%) 14 (60.1%)
N1 18 (39.1%) 2 (66.7%) 8 (40.0%) 8 (34.8%)
N2 2 (4.3%) 0 1 (5.0%) 1 (4.3%) NS
Cases with extranodal extension 8 (17.4%) 0 5 (25.0%) 3 (13.0%) NS
MARGINS
Clear 29 (48.3%) 1 (33.3%) 12 (48.0%) 16 (50.0%)
Involved 15 (25.0%) 0 6 (24.0%) 9 (28.1%)
Not assessable 16 (26.7%) 2 (66.7%) 7 (28.0%) 7 (21.9%) NS
DCIS
Absent 14 (25.0%) 0 7 (29.2%) 7 (24.1%)
NA 4 0 1 3
Present 42 (75.0%) 3 (100%) 17 (70.8%) 22 (75.9%) NS
Nuclear Grade
Low 2 (4.8%) 0 2 (11.8%) 0
Intermediate 26 (61.9%) 1 (33.3%) 10 (58.8%) 15 (68.0%)
High 14 (33.3%) 2 (66.7%) 5 (29.4%) 7 (31.8%) NS
NS – Not significant.
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Clinical parameters, including TNM staging, tumour re-
currence, occurrence of non-breast primary tumours
and death were obtained from referring clinical centres,
kConFab questionnaires and state death registries. Infor-
mation on pedigree, mutational status and testing were
available from the kConFab central registry. All available
slides from all cases were reviewed by a pathologist for
relevant histopathological parameters. Histological clas-
sification was based on criteria set by the World Health
Organisation. This work was carried out with approvalfrom the Peter MacCallum Cancer Centre Ethics Com-
mittee (Project No: 11/61).
Mutation detection
Mutation test results were generated through two avenues.
If a clinic had performed mutation screening, the clinic re-
port was passed onto the kConFab central registry. If no
clinic mutation testing had been performed, the kConFab
core research laboratory performed mutation testing.
Testing for BRCA1 and BRCA2 mutations was performed
on DNA extracted from 18 ml sample of anticoagulated
Figure 1 Mutation carrier status and age of diagnosis.
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col [21] generated a nucleated cell product for DNA ex-
traction. DNA was extracted as required (QIAamp DNA
blood kit, Qiagen GmbH, Hilden, Germany). Testing of
index cases in kConFab families was carried out by de-
naturing high performance liquid chromatography or
multiplex ligation-dependent probe amplification [22].
BRCA1 and BRCA2 variants were classified into the fol-
lowing categories with criteria as posted on kConFab's
website [23]: pathogenic, splice-site variant, variant of un-
known significance and polymorphism. Once the family
mutation had been identified, all pathogenic (including
splice site) variants of BRCA1 and BRCA2 were genotyped
by kConFab in all available family members' DNA.
Tissue microarrays (TMAs) and expression analysis by
immunohistochemistry (IHC)
TMAs were created from archival paraffin material. Two
1mm cores were taken for each tumour. TMA sections
were cut at 4 μm thick intervals, de-waxed and hydrated.
Antigen retrieval was performed according to manufac-
turers’ instructions and endogenous peroxidase activity
blocked before incubating sections with desired antibodies.
Tumours were separated into molecular phenotypes as per
Nielsen et al [24]. Expression of estrogen receptor-α (ER)
(Ventana, clone SP1), progesterone receptor (PgR) (Ven-
tana, clone 1E2), epidermal growth factor receptor (EGFR)
(Zymed, clone 31G7) and cytokeratin (CK) 5 (Cell Marque,
clone EP1601Y) was performed. HER2 amplification was
assessed by silver in situ hybridisation (SISH) using the IN-
FORM HER2 DNA probe (Ventana). Nuclear expression of
ER and PgR was scored as per the Allred scoring system
[25] (intensity + percentage of tumour cells staining, 0–8)
and separated into absent (score 0/8), low (1-5/8) and high
(6-8/8). HER2 gene status was reported as the average
number of copies of the HER2 gene per cell in 30 tumour
cells. Gene status was assessed as per the guidelines recom-
mended by Wolff et al [26]. EGFR was scored positive for
any membranous staining of tumour cells. Expression of
CK5 was defined as positive when cytoplasmic and/or
membranous staining was observed in tumour cells.
Tumours were assigned to the following subtypes; Luminal
(ER positive, HER2 negative), HER2 (HER2 positive), Basal
(ER PgR and HER2 negative, CK5 and/or EGFR positive),
and Null/negative (ER, PgR, HER2, CK5/6 and EGFR
negative).
Statistical analysis
Comparison of groups was made with using Mann–
Whitney U for non-parametric continuous distributions
and chi-square test for threshold data. Kaplan-Meier
survival curves were plotted using breast cancer related
death as the endpoint and compared using a log rank
test. Regression analyses as time to fail curves wereplotted for age of diagnosis and occurrence of second
non breast primary tumours. Cox proportional hazard
regression model was used to identify independent prog-
nostic factors for disease specific survival (DSS). Analysis
was performed with GraphPad Prism 5 software (Graph-
Pad Prism version 5.04 for Windows, GraphPad Soft-
ware, La Jolla California USA). A two-tailed P-value test
was used in all analyses and a P-value or less than 0.05
was considered statistically significant.
Results
Mutation analysis
The prevalence of MBCs in the kConFab registry with
known gene mutations is summarised in Table 1 and 2.
There were 5 (1.2%) of 429 known BRCA1 mutation car-
riers and 35 (10.3%) of 339 BRCA2 carriers who devel-
oped breast cancer. Of these, 3 and 25 cases respectively
had reports, slides and tissues available for examination
and were included in the study. Of the 3 BRCA1 cases, 2
had a pathogenic mutation with 1 large genomic re-
arrangement. Of the 25 BRCA2 cases, 22 had a patho-
genic mutation, 2 large genomic rearrangements and 1
an unclassified variant. Within non-BRCA1/2 families, of
a total of 19,137 males, 78 (0.4%) developed breast can-
cer with 32 cases available for use in the study.
Clinicopathological features
The clinicopathological features are summarised in
Table 3. The overall median age of diagnosis was 62.5
years (range 30.1-85.6 years), and mean age of diagnosis
60.0 years. There was no significant difference in clinico-
pathological factors between BRCA1, BRCA2 carriers
and BRCAX males including age of onset (Figure 1).
Surgical treatment was by wide local excision (33.3%,
20/60) and mastectomy (66.6%, 40/60). All tumours
Figure 2 H&E histological subtypes in male breast cancer: a) invasive ductal carcinoma of no special type, b) & c) invasive lobular
carcinoma, d) & e) invasive papillary carcinoma, f) invasive micropapillary carcinoma.
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the nipple. Four cases (6.6%) had multifocal disease with
2 cases of bilateral breast cancer, of which one was a
metachronous BRCAX tumour with a 10 year interval
and the other a BRCA2 carrier with contralateral tumour
occurring 12 years after the primary lesion.
Tumour size ranged from 2 mm to 50 mm (median
17 mm). The most common histological subtype was infil-
trating ductal carcinoma of no special type (IDC-NST)
(90%, 54/60) (Figure 2a) with 2 cases of invasive lobular
carcinoma (3.3%) (Figure 2b and c) and 4 cases of invasive
papillary carcinoma (6.7%) (Figure 2d and e). Of theFigure 3 Immunohistochemical staining of male breast cancer for ERIDC-NST tumours, 8 had areas between 15 to 40% of
invasive micropapillary carcinoma (Figure 2f ).
Tumours were of mainly grade 2 (51.7%) and grade 3
(45.0%). Lymphovascular and perineural invasion (PNI)
was identified in 42.9% (24/56) and 43.6% (24/55) of
cases respectively when able to be assessed. Paget’s in-
volvement of the nipple was seen in 15.4% of cases (8/52)
when assessable. Most tumours had a component of DCIS
present (75%, 42/56). Normal breast tissue and gynaeco-
mastia was observed in 65.1% (28/43) and 11.6% (5/43)
of cases respectively. Forty six cases had lymph node
sampling with 7 sentinel node biopsy only (15.2%) andand PgR.
Figure 4 HER2 SISH demonstrating HER2 amplification in male
breast cancer.
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1.6 sentinel nodes (median 1, range 1–3) were examined
and an average of 15 nodes from axillary dissections
(median 13, range 4–30). Of these, 1 (14.3%) sentinel
node had metastatic disease and 19 axillary dissections
had positive nodal disease (48.7%) with extranodal ex-
tension in 8 cases.
Most tumours were ER and PgR positive (Additional
file 2: Figures S1 and Additional file 3: Figure S2), withFigure 5 Male breast cancer of basal cell phenotype: a) H&E, b) CK5,89.7% (52/58) and 77.2% (44/57) of cases respectively
scored as high (Allred score 6-8/8) (Figure 3). HER2
amplification was seen in 9.1% (5/55) of cases (Figure 4).
The range of HER2 amplification was 6.1-10.5 signals
per nuclei in amplified cases. Two tumours were unable
to be immunophenotyped completely. Based on analysis
of the remainder, the most common intrinsic subtype was
Luminal (89.7%, 52/58) followed by HER2 (8.6%, 5/58)
and Basal (1.7%, 1/58). The Basal subtype (Figure 5) was a
BRCAX tumour with prominent CK5 and EGFR staining
but also low ER nuclear positivity. Morphology of this
tumour was more consistent with a basal subtype rather
than a luminal type tumour.
There was a trend towards BRCA2 tumours having an
invasive micropapillary component (24% 6/25, p=0.0574)
and high Bloom Richardson Ellis (BRE) grade for BRCA1
tumours (100% grade 3 3/3, p=0.0855), however these
observations did not reach statistical significance. Over-
all, clinicopathological factors and intrinsic subtypes
were not associated with BRCA1 or 2 mutation carrier
status and unlike in female breast cancer [27], there was
no association between BRCA1 mutational status and
basal cell phenotype.
Characteristics are compared with other recent large
MBC studies containing >50 patients and completed
within the last 4 years [6-8,28-40] (Additional file 4:
Table S2) and with the previous study of female breast
cancers within the kConFab cohort [41].c) ER, d) PgR.
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The overall 5 and 10 year disease specific survival rates
were 84.6% and 40.6% for all cases, 100% and 0% for
BRCA1 case, 80.6% and 42.2% for BRCA2 cases and
86.7% and 41.2% for BRCAX cases (Figure 6). Clinico-
pathological variables (Figure 7) that were of prognostic
significance for DSS included a primary tumour size
>2.0 cm (HR:4.26 95%CI 1.63-11.11, p=0.003), age at diag-
nosis > 65 years (HR:4.09 95%CI 1.65 -10.12, p=0.002),
lymphovascular invasion (HR:3.25 95%CI 1.21-8.74,
p=0.019) and PNI (HR:2.82 95% CI 1.13-7.06, p=0.027)
(Table 4). A strong adverse trend for loss or low progester-
one receptor expression was also seen (HR:2.59 95%CI
0.86-7.80, p=0.091) but fell short of being statistically
significance.
Comparisons of mutation carrier status, tumour grade,
presence of nodal disease, involvement of surgical mar-
gins and multifocality were not prognositically signifi-
cant (all p>0.05).
Second cancers
Ten patients had a second major malignancy (5/25
BRCA2 mutation carriers, 5/31 BRCAX cases) (Table 5).
No BRCA1 patients developed a second malignancy. In
eight (80%) cases, the diagnosis of the primary breast
tumour was the sentinel event while in two cases (20%)
another malignancy was diagnosed preceding the breast
cancer. The median time to diagnosis was 3.8 years after
the diagnosis of the breast cancer (range 3 years previ-
ous to 15.5 years after). The most common second malig-
nancy was prostatic acinar adenocarinoma (50%, 5/10). Of
note, one patient had an adenocarcinoma of the abdom-
inal wall of unknown primary origin with exclusion of a
breast metastasis. Mutation carrier status was not prog-
nostic of development of a second malignancy when com-
paring BRCA2 and BRCAX cohorts (Figure 8).Figure 6 Mutation carrier status and disease specific survival.Discussion
To the best of our knowledge this is the largest high-risk
population based study to date describing the genotypic,
conventional clinicopathological and intrinsic pheno-
typic characteristics of MBCs arising within breast can-
cer families. Previous studies have either not contained
large numbers of patients with a significant family his-
tory [30,34,35,37,43,47], not commented or examined
family history [6-8,28,29,36,39,40], or have contained
large numbers of such cases with strong family pedigree
but not described clinicopathological features [32] (Table 4).
As a large proportion of MBCs are purported to arise in
families with breast cancer and in particular BRCA2
mutation carriers, further description of this cohort is
of significance in understanding and characterising the
disease.
The incidence of MBC in BRCA2, BRCA1 and BRCAX
males is significantly higher than the lifetime cumulative
incidence of 0.1% in the general population [17,48] con-
firming this group as a high risk for MBC. However, the
representation of carriers is different to that of familial
FBC with direct comparison within the kConFab registry
[41] showing an increased proportion of BRCA2 male car-
riers and underrepresentation of BRCA1 male tumours.
This suggests that significant gender associated modifiers
such as high estrogen levels may affect BRCA1 penetrance
over BRCA2. Comparing studies of sporadic MBC [6-8,
28-32,35,37-40,44], the median and mean age of onset in
our patients is also younger, and this together with the ob-
servation of frequent multifocality or bilateral disease
reflects the pattern of cancer often seen with underlying
genetic predisposition as seen in familial FBC. A recent
large population based study by Ottini et al. [45] contain-
ing 46 BRCA2 mutation carriers also observed a high rate
(15.2%) of contralateral breast cancer in these carriers,
thus supporting this observed pattern.
Compared with other MBC groups, our study appeared
to have a higher proportion of high grade tumours with
only 3.3% of tumours of BRE grade I, the lowest within
any MBC cohort reported to date. We also reported the
highest proportion of invasive papillary carcinomas with
6.7% of cases, the next highest in the literature being 5.5%
by Ottini et al. [45]. The histopathological tumour charac-
teristics of our group otherwise is comparable to that seen
in previous studies of sporadic MBC with the majority of
cancers being invasive ductal carcinoma. This is higher
than that seen in FBCs from kConFab [41]. Unlike FBC,
we also observed proportionately less lobular carcinoma
which is thought to reflect paucity of lobular and acinar
units in males [49].
We also report a relatively higher proportion of
tumours with invasive micropapillary areas particularly
within BRCA2-associated tumours, an association not
previously reported. Recent studies suggest that these
Figure 7 (See legend on next page.)
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Figure 7 Clinicopathological variables and disease specific survival: (a) BRE grade, (b) lymphovascular invasion, (c) perineural invasion,
(d) primary tumour size, (e) Paget’s disease of the nipple, (f) nodal status, (g) age at diagnosis, (h) histological subtype, (i) Intrinsic
phenotype, (j) PgR immunohistochemical expression, (k) ER immunohistochemical expression, (l) HER2 amplification, (m) involvement
of margins, (n) diagnosis of second non breast primary malignancy, (o) multifocal disease.
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iour than IDC-NST [50]. The distinct histological fea-
tures of these tumours correlate with distinct molecular
genetic profiles [42], however, in female cancer a correl-
ation with BRCA2 mutation has not been described or
suggested [10]. Ottini et al [45], also describe a BRCA2
MBC phenotype with a high proportion of BRE grade 3
tumours (54.8%), loss of PgR expression (67.9%) and
HER2 amplification (63.2%). Similar to them, our BRCA2
carriers contained a large proportion of BRE grade 3 but
was not significantly different to the BRCA1 and
BRCAX population. The expression of ER and PgR in
our familial MBCs is similar to that seen in sporadic
MBC, with proportionately higher levels than seen in
FBC, and absence of PgR expression did not discrimin-
ate a BRCA2 phenotype. Subsequently, the majority of
our cases were also of the luminal subtype. Reported
HER2 amplification in MBC has been more variable
than ER and PgR with studies demonstrating between
3.3% [40] to 28.4% [45] of cases showing HER2 amplifi-
cation. While our study and Ottini are the only to date
to examine the association with BRCA status, using
routine diagnostic testing for HER2 we see lower fre-
quency of HER2 amplification both overall (9.1%) and
within our BRCA2 carriers (8.3%) as a subgroup. Our
results are consistent with most MBC studies that sug-
gest HER2 amplification is seen half as frequently as
that in FBC [41].
The few numbers of BRCA1 MBCs in our cohort pre-
cludes extensive clinicopathological analysis, however, in
contrast and unlike tumours seen in BRCA1 female car-
riers [27,51], cancers of medullary/basal cell phenotype
in BRCA1 males has not been reported in the literature
and was also not observed in our cohort of BRCA1






Lymphovascular Invasion 0.0194 3.25 1.21 - 8.74
Perineural Invasion 0.0266 2.82 1.13 - 7.06
Tumour Size > 20mm 0.0030 4.26 1.63 - 11.11
Age of Diagnosis > 65 years 0.0024 4.09 1.65 - 10.12
Low Progesterone
Receptor Expression
0.0909 2.59 0.86 - 7.80cohort overall also reflected observations of other MBC
studies.
Several prognostic markers in our study are also
reported in both FBC and sporadic MBC. In our study,
we confirmed many but also identified PNI as being of
prognostic significance, which has not been reported
previously in MBC. Its presence, being double most
rates reported in FBC [52,53], may be due to frequent
subareolar tumour location which is less frequently seen
in women, and comparable to frequent perineural in-
volvement seen in other epithelial tumours such as pan-
creatic [54] and prostatic [55] adenocarcinoma where
the organs have closer proximity to nerve bundles.
While mixed prognostic significance of PNI has been
seen in FBC studies [53], PNI positive tumours have
been shown to be more often associated with positive
nodal status and hormonal positivity [53], both of which
are more commonly seen in MBC in general, and in our
study cohort when compared with FBC.
While our numbers are not large, a considerable propor-
tion (16.6%) of the BRCA2 and BRCAX patients devel-
oped a second non-breast primary malignancy. The onset
or histological type of these tumours did not correlate
with mutation carrier status. These findings are consistent
with those previously reported in MBC cohorts where the
range of second cancer incidence varies between 5.9% to
22.8% when reported [8,28,30,31,34,35]. Notably, the stud-
ies with higher rates of breast cancer families such as Ding
[31] (60% either BRCA2 pathogenic mutation carrier or
strong family history of breast cancer), Liukkonen[35]
(33.1% with significant familial history) and Kiluk [34]
(29% with significant familial history) had 22.8%, 19% and
19.4% of their patients reporting a second primary respect-
ively. Of the types reported, prostate cancer was the most
common followed by bladder cancer, a tumour type not
seen in our cohort. In recent studies we and others have
demonstrated the relative risk for developing prostate can-
cer in male BRCA2 mutation carriers as between 2.9 to
4.8 times the general population [56-59]. Comparing our
study with the age related rate of Australian males in the
60–64 year age group, there is an increased relative risk of
prostate cancer of 19.08 (p<0.0001, 95%CI 4.50-80.91) and
20.56 (p<0.0001, 95%CI 6.30-67.12) times the normal
population for BRCA2 and BRCAX male patients with
breast cancer respectively. These data show that patients
with MBC may be a high-risk group for developing second
malignancies, even when comparing with BRCA2 carriers
Table 5 Second non-breast primary malignancies
Gene Mutation 2nd tumour Diagnosis relative to Breast Primary (years)
BRCA2 BRCA2 2988 del C (STOP 959) Ascending Colon - Adenocarcinoma 15.5
BRCA2 BRCA2 698_702 del AGTCA (STOP 180) Prostate - Acinar Adenocarcinoma 0.8
BRCA2 BRCA2 8168_8169 ins C (STOP 2661) Prostate - Acinar Adenocarcinoma 1.4
BRCA2 BRCA2 del exons 1_27 Parotid gland - Oxyphilic adenocarcinoma 6.2
BRCA2 BRCA2 IVS 7–1 G>A Lung - squamous cell carcinoma 13.8
BRCAX Adenocarcinoma - unknown primary 3.0
BRCAX Lung – Carcinoma not otherwise specified. 9.4
BRCAX Prostate - Acinar Adenocarcinoma 9.5
BRCAX Prostate - Acinar Adenocarcinoma 3.0 years prior to breast cancer
BRCAX Prostate - Acinar Adenocarcinoma 1.3 years prior to breast cancer
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driving both tumour types or underlying genetic factors
requires further study in a larger data set.
Conclusions
This is the largest clinicopathological study of male breast
cancers arising in breast cancer families. It identifies three
high-risk population groups (BRCA1/2, BRCAX) which
may be important for screening for male breast cancer.
The clinical and pathological characteristics are different
to familial female breast cancer but similar to previously
described male breast cancer studies which have contained
but not separately analysed sporadic and familial breast
cancers. Notably, our study in comparison contains pro-
portionately more multifocal disease, a younger age of
onset and a significant proportion with a second major
malignancy, features often seen in tumours that arise with
a genetic predisposition. BRCA2 mutation status did not
appear to correlate with a distinct clinicopathological
phenotype or disease behaviour, and a strong trend was
seen within BRCA2 carrier tumours containing areas ofFigure 8 BRCA status and onset of second malignancy.micropapillary carcinoma possible suggesting a possible
BRCA2 male breast cancer phenotype. Further subgroup
analysis, in particular of BRCA1 tumours, was limited by
the number of cases available. Further recruitment of well
characterised tumours in breast cancer families, in par-
ticular a focused collection of BRCA1 cases, is warranted
to validate and characterise familial MBC further.
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